CAS: 1690307-05-1
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Obexelimab REF: TM-T81624CAS: 1690307-05-1 | 95% - 95% | 275.00 €~1,846.00 € | Wed 18 Dec 24 |
 | Obexelimab REF: 3D-CLA1371CAS: 1690307-05-1 | - - - | To inquire | Mon 30 Dec 24 |
Obexelimab
CAS:1690307-05-1
ACBI3 is a pan-KRAS degrader with anticancer activity, degrading oncogenic KRAS.
Purity:
95% - 95%
Color and Shape:
Liquid
Ref: TM-T81624
| 1mg | 275.00 € | ||
| 5mg | 678.00 € | ||
| 10mg | 924.00 € | ||
| 25mg | 1,396.00 € | ||
| 50mg | 1,846.00 € |
Estimated delivery in United States, on Wednesday 18 Dec 2024
Obexelimab
CAS:1690307-05-1
Anti-CD19 and Fc gamma receptor IIb humanized monoclonal antibody; treatment of lupus and IgG4 related …
Ref: 3D-CLA1371
| Undefined size | To inquire |
Estimated delivery in United States, on Monday 30 Dec 2024
